A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Patients 18 years of age and older with clinical stages IIA, IIB, IIIA, IIIB, IVA cervical carcinoma limited to the pelvis will receive twice daily oral nelfinavir (NFV) and weekly IV cisplatin in combination as radiosensitizers with daily whole pelvic external beam and intracavitary radiation brachytherapy.

See also
Status	Clinical Trial	Phase
Completed	`NCT05022511` - Three Birds With One Stone	N/A
Not yet recruiting	`NCT06331468` - Hypofractionated Radiochemotherapy	Phase 2
Completed	`NCT03296566` - The SAFE Study: Satisfaction and Adherence to Follow-Up With Colposcopy Exams	N/A
Recruiting	`NCT05462951` - Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer	N/A

NCT number	NCT02363829
Study type	Interventional
Source	Abramson Cancer Center of the University of Pennsylvania
Contact
Status	Completed
Phase	Phase 1
Start date	February 2015
Completion date	February 17, 2020

A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms